Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05522231 | Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | PHASE2/PHASE3 | ACTIVE NOT_RECRUITING | 265 | — | — | Oct 1, 2022 | Mar 1, 2025 | Jan 2, 2025 | - | — |
| Name | Type | Description |
|---|---|---|
| fruquintinib+sintilimab | DRUG | fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle. |
| axitinib / everolimus | DRUG | axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion based on clinical; everolimus, 10 mg, QD, PO, 3 weeks/cycle. |
| fruquintinib | DRUG | fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle. |